Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POU2F2 | P09086 | 7/20 | 0.45 |
| ▸ | SLC22A2 | O15244 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82602 | 0.85 | POU2F2 (0.51) | POU2F2SLC22A2MAPTLMNA | |
| SCHEMBL2187039 | 0.85 | POU2F2 (0.44) | POU2F2SLC22A2 | |
| SCHEMBL81275 | 0.78 | POU2F2 (0.50) | POU2F2SLC22A2MAPTLMNA | |
| SCHEMBL2186003 | 0.76 | POU2F2 (0.45) | POU2F2SLC22A2 | |
| SCHEMBL22482391 | 0.74 | POU2F2 (0.50) | POU2F2SLC22A2MAPT | |
| SCHEMBL22469550 | 0.74 | POU2F2 (0.50) | POU2F2SLC22A2MAPT | |
| SCHEMBL3527796 | 0.73 | LIPG (0.43) | POU2F2SLC22A2 | |
| SCHEMBL19071705 | 0.73 | SLC22A2 (0.47) | POU2F2SLC22A2 | |
| SCHEMBL19072174 | 0.73 | SLC22A2 (0.47) | POU2F2SLC22A2 | |
| SCHEMBL3522619 | 0.73 | POU2F2 (0.48) | POU2F2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273065-B2 | Substituted pyrido[1',2':4,5]pyrazino[1,2-a]pyrimidines as HIV integrase inhibitors | SHIONOGI & CO., LTD. (JP) | 2016-03-01 | — | — | US | disclosed |
| US-20150232479-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232479-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | POU2F2 668/4885SLC22A2 2899/4885MAPT 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.